Management of L-Dopa related hyperhomocysteinemia: Catechol-O- methyltransferase (COMT) inhibitors or B vitamins? Results from a review

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 12, 2007, Pages 1607-1613

  Zoccolella, Stefano ^a   Iliceto, Giovanni ^a   DeMari, Michele ^a   Livrea, Paolo ^a   Lamberti, Paolo ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Cobalamin; Entacapone; Folate; Homocysteine; L Dopa; Parkinson's disease; Tolcapone

Indexed keywords

CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; COBALAMIN; ENTACAPONE; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; PLACEBO; VITAMIN B GROUP;

ABSENCE OF SIDE EFFECTS; AMINO ACID BLOOD LEVEL; CARDIOVASCULAR RISK; CONFERENCE PAPER; CORRELATION ANALYSIS; CYTOTOXICITY; DIET SUPPLEMENTATION; DRUG EFFECT; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; NERVE CELL; PARKINSON DISEASE; PRIORITY JOURNAL; VITAMIN SUPPLEMENTATION;

CATECHOL O-METHYLTRANSFERASE; ENZYME INHIBITORS; HUMANS; HYPERHOMOCYSTEINEMIA; LEVODOPA; VITAMIN B COMPLEX;

EID: 36849088639     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.337     Document Type: Conference Paper

References (49)

1. Marsden CD. Parkinson's disease. Lancet 1990;335:948-52.
2. Daly D, Miller JW, Nadeau MR, Selhub J. The effect of L-dopa administration and folate deficiency on plasma homocysteine concentrations in rats. J Nutr Biochem 1997;8:634-40.
3. Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA. Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 1997;20:55-66.
4. Allain P, Le Bouil A, Cordillet E, LeQuay L, Begheri H, Montastruc JL. Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology 1995;16:527-9.
5. Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Przuntek H, Kretschmer A, et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 1998;40:225-7.
6. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effects of L-Dopa on plasma homocysteine in PD patients. Relationship to B-vitamin status. Neurology 2003;60:1125-9.
7. Muller T, Werne B, Fowler B, Kuhn W. Nigral endothelial dysfunction, homocysteine and Parkinson's disease. Lancet 1999;354:126-7.
8. Kuhn W, Hummel T, Woitalla D, Muller T. Plasma homocysteine and MTHFR C677T genotype in levodopa treated patients with PD. Neurology 2001;56:281-2.
9. Brattstrom L. Plasma homocysteine and MTHFR C677T genotype in levodopa treated patients with PD. Neurology 2001;56:281.
10. Blandini F, Fancellu R, Martignoni E, Mangiagalli A, Pacchetti C, Samuele A, et al. Plasma homocysteine and L-Dopa metabolism in patients with Parkinson's disease. Clin Chem 2001;47:1102-4.
11. Muller T, Woitalla D, Hauptmann B, Fowler B, Kuhn W. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci Lett 2001;308:54-6.
12. Woitalla D, Kuhn W, Muller T. MTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson's disease. J Neural Transm Suppl 2004;64:15-20.
13. O'Suilleabhain PE, Diaz-Arrastia R. Levodopa elevates homocysteine: is this a problem? Arch Neurol 2004;61:633-4.
14. Postuma RB, Lang A. Homocysteine and levodopa. Should Parkinson disease patients receive preventative therapy? Neurology 2004;63:886-91.
15. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa treated patients with PD. Neurology 2000;55:437-40.
16. Yasui K, Nakaso K, Kowa H, Takeshima T, Nakashima K. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol Scand 2003;108:66-7.
17. O'Suilleabhain PE, Bottiglieri T, Dewey RB, Sharma S, Diaz-Arrastia R. Modest increase in plasma homocysteine follows Levodopa initiation in Parkinson's disease. Mov Disord 2004;19:1403-8.
18. Olanow CW, Stocchi F. COMT inhibitors in Parkinson's disease. Can they prevent and/or reverse levodopa-induced motor complications? Neurology 2004;62(Suppl 1):S72-81.
19. Nakaso K, Yasui K, Kowa H, Kusumi M, Ueda K, Yoshimoto Y, et al. Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with levodopa, homocysteine and MTHFR genotype. J Neurol Sci 2003;207:19-23.
20. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with Levodopa. Arch Neurol 2003;60:59-64.
21. Lee ES, Chen H, Soliman KF, Charlton CG. Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology 2005;26:361-71.
22. Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 1997;94:5923-8.
23. Muller T, Renger K, Kuhn W. Levodopa associated homocysteine increase and sural axonal neurodegeneration. Arch Neurol 2004;61:657-60.
24. Muller T, Kuhn W. Neurotoxicity of levodopa: treatment-associated homocysteine increase. Nat Clin Pract Neurol 2007;3:E1.
25. Parkinson Study Group. Entacapone improves motor fluctuations in Levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-55.
26. Nissinen E, Nissinen H, Larjonmaa H, Vaananen A, Helkamaa T, Reenila I, et al. The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats. J Neural Trans 2005;112:1213-21.
27. Krause M, Okun JG, Wang Q, Schwab S, Henninger N. Entacapone but not folate prevents L-dopa induced hyperhomocysteinemia wabstractx. Mov Disord 2005;20(Suppl 10):S101.
28. Lamberti P, Zoccolella S, Iliceto G, Armenise E, Fraddosio A, de Mari M, et al. Effects of levo-dopa and COMT inhibitors on plasma homocysteine in PD patients. Mov Disord 2005;20:69-72.
29. Zoccolella S, Lamberti P, Armenise E, de Mari M, Lamberti SV, Mastronardi R, et al. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. Park Relat Disord 2005;11:131-3.
30. Valkovic P, Benetin J, Blazicek P, Valkovicova L, Gmitterova K, Kukumberg P. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson's disease patients. Park Relat Disord 2005;11:253-6.
31. Nevrly M, Vranova H, Ressner P, Nestrasil I, Kanovsky P. Effect of L-Dopa and entacapone on plasma Hcy level in Parkinson's disease. Pilot study wabstractx. Mov Disord 2006;21(Suppl 15):S545.
32. Ostrem JL, Kang GA, Subramanian I, Guarnieri M, Hubble J, Rabinowicz AL, et al. The effect of entacapone on homocysteine levels in Parkinson disease. Neurology 2005;64:1482.
33. Zesiewicz T, Wecker L, Sullivan KL, Merlin LR, Hauser RA. The controversy concerning plasma homocysteine in Parkinson disease patients treated with Levodopa alone or with entacapone: effects of vitamin status. Clin Neuropharmacol 2006;29:106-13.
34. Postuma RB, Lang AE. Vitamins and entacapone in Levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology 2006;66:1941-3.
35. Nissinen H, Ellmen J, Vahteristo M. Entacapone significantly decreases elevated plasma homocysteine levels in levodopa-treated Parkinson's disease patients wabstractx. Mov Disord 2005;20(Suppl 10):S94.
36. Muller T, Kuhn W. Tolcapone decreases plasma levels of S-adenosyl homocysteine and homocysteine in treated Parkinson's disease patients. Eur J Clin Pharmacol 2006;62:447-50.
37. Lavie L, Lavie P. Daily rhythms in plasma levels of homocysteine. J Circadian Rhythms 2004;2:1-6.
38. Selhub J, Jacques PF, Wilson PW, Rush D, Rosemberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. J Am Med Assoc 1993;270:2693-8.
39. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001;345:1593-600.
40. He K, Merchant A, Rimm EB, Rosner BA, Stampfer MJ, Willett WC, et al. Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men. Stroke 2004;35:169-74.
41. Lamberti P, Zoccolella S, Armenise E, Lamberti SV, Fraddosio A, de Mari M et al. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. Eur J Neurol 2005;12:365-8.
42. Camicioli RM, Somerville M, Bouchard T, Acharya H, Martin W. Homocysteine in older Parkinson's disease patients is associated with dyskinesias and influenced by methylenetetrahydrofolate reductase (MTHFR) genotype and over-the-counter B-vitamin use wabstractx. Neurology 2007;68(Suppl 1):A259.
43. Di Rocco A. Vitamins and entacapone in Levodopainduced hyperhomocysteinemia: a randomized controlled study. Neurology 2007;68:1440.
44. Postuma RB, Lang AE. Vitamins and entacapone in Levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology 2007;68:1441.
45. Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, et al. DACH-LIGA homocysteine (German, Austrian and Swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med 2003;41:1392-403.
46. de Lau LM, Koudstaal PJ, Witteman JC, Hofman A, Breteler MM. Dietary folate, vitamin B12 and vitamin B6 and the risk of Parkinson's disease. Neurology 2007;67:315-8.
47. Zhao WQ, Latinwo L, Liu XX, Lee ES, Lamango N, Charlton CG. L-Dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase. Exp Neurol 2001;171:127-38.
48. Mattson MP. Methylation and acetylation in nervous system development and neurodegenerative disorders. Brain Res 2001;893:278-81.
49. Muller W, Przuntek H. Therapy with central active catechol-O- methyltransferase (COMT)-inhibitors: is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders? J Neural Transm Gen Sect 1993;92:187-95.